Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Filed Aug 8, 2013 · 10-Q · 39 days after period end · 0001393905-13-000403
| Metric | Q2 2013 | Q2 2012 |
|---|---|---|
| Revenue | $97.28K | $97.02K |
| Net Income | -$726.57K | -$475.08K |
| EPS Diluted | -$0.34 | -$0.31 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Jun 30, 2013 · filed Aug 8, 2013 · 39 d after period end
